Episurf Medical enters into licensing agreement of SEK 1.5m for µiFidelity® software platform
Episurf Medical (Nasdaq: EPIS B) today announces that the company enters into an agreement of SEK 1.5m for out-licensing of the µiFidelity® software platform. The platform constitutes the communication and distribution platform for Episurf Medical’s orthopaedic product line, where medical imaging constitutes a central part. By the transaction, the company is licensing its platform to a US-based orthopaedic company, which intends to establish its own communication and distribution platform based on µiFidelity®.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on 22 December 2020.
Tags: